Open AccessDecreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia
Author(s) -
TOOZE J. A.,
BEVAN D. H.
Publication year - 1991
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1991.tb05655.x
Subject(s) - flow cytometry , monoclonal antibody , immunology , complement receptor , chronic lymphocytic leukemia , antibody , b cell , biology , phenotype , complement system , leukemia , biochemistry , gene
SUMMARY Neoplastic cells from 49 patients with B cell chronic lymphocytic leukaemia (B‐CLL) were studied and compared with normal peripheral and tonsillar B cells using CD2I monoclonal antibodies. Membrane expression of CR2 was quantified by calibrated flow cytometry and by binding analysis with radiolabelled antibody. Both assays indicate that B‐CLL cells express only 30% of the CR2 found on normal B cells. These findings are further evidence of the aberrant phenotype of B‐CLL cells.